Skip to main content

Table 2 Sero-prevalences of HSV type 1 and 2 according to cancer history-NHANES 1999–2014

From: Seropositivity to herpes simplex virus type 2, but not type 1 is associated with cervical cancer: NHANES (1999–2014)

Variable

Status

HSV1+ number

HSV1- number

HSV1+ weighted percent

s.e.

P value

Any cancer

Yes

229

93

67.17

3.12

0.04

 

No

5231

2631

60.39

0.91

 

Breast cancer

Yes

24

8

76.16

8.44

0.11

 

No

5436

2716

60.65

0.90

 

Cervical cancer

Yes

88

40

65.23

5.75

0.44

 

No

5372

2684

60.64

0.90

 

Ovarian cancer

Yes

21

3

77.82

11.77

0.22

 

No

5439

2721

60.68

0.90

 

Uterine cancer

Yes

30

4

92.24

4.51

<0.01

 

No

5430

2720

60.61

0.90

 

Variable

Status

HSV2+ number

HSV2- number

HSV2+ weighted percent

s.e.

P value

Any cancer

Yes

119

203

34.26

3.51

<0.01

 

No

2144

5718

24.54

0.66

 

Breast cancer

Yes

8

24

23.64

9.23

0.88

 

No

2255

5897

25.02

0.64

 

Cervical cancer

Yes

56

72

40.05

5.41

<0.01

 

No

2207

5849

24.74

0.65

 

Ovarian cancer

Yes

11

13

44.41

12.95

0.09

 

No

2252

5908

24.96

0.65

 

Uterine cancer

Yes

15

19

57.99

11.61

<0.01

 

No

2248

5902

24.89

0.65

 
  1. Abbreviations: HSV1, herpes simplex virus type 1; HSV2, herpes simplex virus type 2; +, positive; −, negative; s.e., standard error; NHANES, National Health and Nutrition Examination Survey